Cargando…

Systematic review of the use of translated patient-reported outcome measures in cancer trials

BACKGROUND: Patient-reported outcomes (PROs) are used in clinical trials to assess the effectiveness and tolerability of interventions. Inclusion of participants from different ethnic backgrounds is essential for generalisability of cancer trial results. PRO data collection should include appropriat...

Descripción completa

Detalles Bibliográficos
Autores principales: Slade, A. L., Retzer, A., Ahmed, K., Kyte, D., Keeley, T., Armes, J., Brown, J. M., Calman, L., Gavin, A., Glaser, A. W., Greenfield, D. M., Lanceley, A., Taylor, R. M., Velikova, G., Turner, G., Calvert, M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074490/
https://www.ncbi.nlm.nih.gov/pubmed/33902699
http://dx.doi.org/10.1186/s13063-021-05255-z
_version_ 1783684363843534848
author Slade, A. L.
Retzer, A.
Ahmed, K.
Kyte, D.
Keeley, T.
Armes, J.
Brown, J. M.
Calman, L.
Gavin, A.
Glaser, A. W.
Greenfield, D. M.
Lanceley, A.
Taylor, R. M.
Velikova, G.
Turner, G.
Calvert, M. J.
author_facet Slade, A. L.
Retzer, A.
Ahmed, K.
Kyte, D.
Keeley, T.
Armes, J.
Brown, J. M.
Calman, L.
Gavin, A.
Glaser, A. W.
Greenfield, D. M.
Lanceley, A.
Taylor, R. M.
Velikova, G.
Turner, G.
Calvert, M. J.
author_sort Slade, A. L.
collection PubMed
description BACKGROUND: Patient-reported outcomes (PROs) are used in clinical trials to assess the effectiveness and tolerability of interventions. Inclusion of participants from different ethnic backgrounds is essential for generalisability of cancer trial results. PRO data collection should include appropriately translated patient-reported outcome measures (PROMs) to minimise missing data and sample attrition. METHODS: Protocols and/or publications from cancer clinical trials using a PRO endpoint and registered on the National Institute for Health Research Portfolio were systematically reviewed for information on recruitment, inclusion of ethnicity data, and use of appropriately translated PROMs. Semi-structured interviews were conducted with key stakeholders to explore barriers and facilitators for optimal PRO trial design, diverse recruitment and reporting, and use of appropriately translated PROMs. RESULTS: Eighty-four trials met the inclusion criteria, only 14 (17%) (n = 4754) reported ethnic group data, and ethnic group recruitment was low, 611 (13%). Although 8 (57%) studies were multi-centred and multi-national, none reported using translated PROMs, although available for 7 (88%) of the studies. Interviews with 44 international stakeholders identified a number of perceived barriers to ethnically diverse recruitment including diverse participant engagement, relevance of ethnicity to research question, prominence of PROs, and need to minimise investigator burden. Stakeholders had differing opinions on the use of translated PROMs, the impact of trial designs, and recruitment strategies on diverse recruitment. Facilitators of inclusive research were described and examples of good practice identified. CONCLUSIONS: Greater transparency is required when PROs are used as primary or secondary outcomes in clinical trials. Protocols and publications should demonstrate that recruitment was accessible to diverse populations and facilitated by trial design, recruitment strategies, and appropriate PROM usage. The use of translated PROMs should be made explicit when used in cancer clinical trials.
format Online
Article
Text
id pubmed-8074490
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80744902021-04-26 Systematic review of the use of translated patient-reported outcome measures in cancer trials Slade, A. L. Retzer, A. Ahmed, K. Kyte, D. Keeley, T. Armes, J. Brown, J. M. Calman, L. Gavin, A. Glaser, A. W. Greenfield, D. M. Lanceley, A. Taylor, R. M. Velikova, G. Turner, G. Calvert, M. J. Trials Review BACKGROUND: Patient-reported outcomes (PROs) are used in clinical trials to assess the effectiveness and tolerability of interventions. Inclusion of participants from different ethnic backgrounds is essential for generalisability of cancer trial results. PRO data collection should include appropriately translated patient-reported outcome measures (PROMs) to minimise missing data and sample attrition. METHODS: Protocols and/or publications from cancer clinical trials using a PRO endpoint and registered on the National Institute for Health Research Portfolio were systematically reviewed for information on recruitment, inclusion of ethnicity data, and use of appropriately translated PROMs. Semi-structured interviews were conducted with key stakeholders to explore barriers and facilitators for optimal PRO trial design, diverse recruitment and reporting, and use of appropriately translated PROMs. RESULTS: Eighty-four trials met the inclusion criteria, only 14 (17%) (n = 4754) reported ethnic group data, and ethnic group recruitment was low, 611 (13%). Although 8 (57%) studies were multi-centred and multi-national, none reported using translated PROMs, although available for 7 (88%) of the studies. Interviews with 44 international stakeholders identified a number of perceived barriers to ethnically diverse recruitment including diverse participant engagement, relevance of ethnicity to research question, prominence of PROs, and need to minimise investigator burden. Stakeholders had differing opinions on the use of translated PROMs, the impact of trial designs, and recruitment strategies on diverse recruitment. Facilitators of inclusive research were described and examples of good practice identified. CONCLUSIONS: Greater transparency is required when PROs are used as primary or secondary outcomes in clinical trials. Protocols and publications should demonstrate that recruitment was accessible to diverse populations and facilitated by trial design, recruitment strategies, and appropriate PROM usage. The use of translated PROMs should be made explicit when used in cancer clinical trials. BioMed Central 2021-04-26 /pmc/articles/PMC8074490/ /pubmed/33902699 http://dx.doi.org/10.1186/s13063-021-05255-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Slade, A. L.
Retzer, A.
Ahmed, K.
Kyte, D.
Keeley, T.
Armes, J.
Brown, J. M.
Calman, L.
Gavin, A.
Glaser, A. W.
Greenfield, D. M.
Lanceley, A.
Taylor, R. M.
Velikova, G.
Turner, G.
Calvert, M. J.
Systematic review of the use of translated patient-reported outcome measures in cancer trials
title Systematic review of the use of translated patient-reported outcome measures in cancer trials
title_full Systematic review of the use of translated patient-reported outcome measures in cancer trials
title_fullStr Systematic review of the use of translated patient-reported outcome measures in cancer trials
title_full_unstemmed Systematic review of the use of translated patient-reported outcome measures in cancer trials
title_short Systematic review of the use of translated patient-reported outcome measures in cancer trials
title_sort systematic review of the use of translated patient-reported outcome measures in cancer trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074490/
https://www.ncbi.nlm.nih.gov/pubmed/33902699
http://dx.doi.org/10.1186/s13063-021-05255-z
work_keys_str_mv AT sladeal systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT retzera systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT ahmedk systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT kyted systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT keeleyt systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT armesj systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT brownjm systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT calmanl systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT gavina systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT glaseraw systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT greenfielddm systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT lanceleya systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT taylorrm systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT velikovag systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT turnerg systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials
AT calvertmj systematicreviewoftheuseoftranslatedpatientreportedoutcomemeasuresincancertrials